4-Aminobenzothieno [3, 2-d] pyrimidines were previously identified in a high throughput screening campaign as LIMK1 inhibitors. Scaffold reversal led to the identification of a series of simple 5, 6-substituted 4-aminothieno [2, 3-d] pyrimidines with low micromolar inhibition of LIMK1.